WallStSmart

Madrigal Pharmaceuticals Inc (MDGL)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Madrigal Pharmaceuticals Inc generates 152527% more annual revenue ($1.13B vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -27.3%. MDGL earns a higher WallStSmart Score of 31/100 (F).

MDGL

Avoid

31

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: -0.82

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDGL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
126.8%10/10

Revenue surging 126.8% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

MDGL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
20.9x2/10

Trading at 20.9x book value

Return on EquityProfitability
-56.9%2/10

ROE of -56.9% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDGL

The strongest argument for MDGL centers on Revenue Growth. Revenue growth of 126.8% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MDGL

The primary concerns for MDGL are EPS Growth, Piotroski F-Score, Price/Book.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

MDGL profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

MDGL is growing revenue faster at 126.8% — sustainability is the question.

MDGL generates stronger free cash flow (-171M), providing more financial flexibility.

Bottom Line

MDGL scores higher overall (31/100 vs 24/100) and 126.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Madrigal Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?